DATA GRAPHICS | Data Byte
CAR T sales: Yescarta continues upward trajectory as Carvykti takes off
Carvykti sales grew 63% while multiple myeloma competitor Abecma dipped
August 5, 2023 1:09 AM UTC
Gilead’s Yescarta continues to dominate CAR T sales for lymphoma, posting seven consecutive quarters of sales growth. Meanwhile, Janssen’s launch of multiple myeloma CAR T Carvykti appeared to take off last quarter as competitor Abecma dipped.
Last year, Gilead Sciences Inc. (NASDAQ:GILD) reported more than $1 billion in sales of Yescarta axicabtagene ciloleucel, making the product the first CAR T therapy to reach blockbuster status, an important commercial proof of principle for the modality. ...